Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
  2. Blood and urine tests detect autism in children
  3. AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?
  4. AAD 2018: AbbVie’s risankizumab boasts strong Phase III data in psoriasis
  5. NHS staff shortages could lead to cutbacks in clinical trials

Latest Content

Phase I Study of Bromodomain Inhibitor OTX015

This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma. 

AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?

At the 76th annual meeting of the American Academy of Dermatology, Johnson & Johnson (J&J) released a cost per responder analysis of their interleukin 23 subunit alpha (IL-23A) inhibitor Tremfya (guselkumab) compared with Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Eli Lilly’s IL-17A inhibitor Taltz (ixekizumab) for the treatment of moderate to severe plaque psoriasis (PsO).

MESM: Expert Medical Equipment Supplier

When every detail matters and when every second counts, expert support makes the difference. MESM has supplied equipment to nearly 2,000 global trials and hit the SIV date 99.9% of the time.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top